Derbyshire Medicines Management and Clinical Policies
Home
Medicines Management
Full Traffic Light Classification
Show Drug
Brolucizumab (Beovu)
Size guide:
A
A
A
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Inappropriate Requests and Prescribing Concerns in Primary Care
Print this page
Add shortcut to your smart phone
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Brolucizumab (Beovu)
Search the site
Search
Status:
Red
Decision Date:
March 2021
Comments
RED:
NICE TA672
: for treating wet age-related macular degeneration.
NICE TA820
:
for treating diabetic macular oedema. (Decision date - September 2022)
search again
Derby and Derbyshire ICB
